ReviewHeart failure reviews2025
Evolving role of echocardiography across the heart failure spectrum: from prevention to advanced management.
Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a global health burden that progresses through identifiable stages from at-risk individuals to symptomatic and advanced disease. Echocardiography has emerged as a cornerstone for precision, stage-based HF management, offering noninvasive evaluation across the entire HF continuum. This review provides an integrated perspective on the evolving role of echocardiography, including newer techniques such as global longitudinal strain (GLS), left atrial (LA) and right ventricular (RV) strain, and multi-organ ultrasound. In Stage A HF, strain imaging allows detection of early myocardial impairment in patients with hypertension, diabetes, or cancer therapy exposure, even when left ventricular ejection fraction is preserved. In Stage B HF, echocardiography identifies structural abnormalities and subclinical dysfunction, with GLS serving as a predictor of progression to symptomatic HF. In Stage C-D HF, echocardiographic parameters, including LA strain and RV function, provide prognostic insight and guide therapy decisions. Pre-discharge echocardiography offers better outcome prediction than admission assessment. Multi-organ approaches, such as lung ultrasound and intrarenal Doppler, complement cardiac imaging in assessing systemic congestion. Throughout all stages, echocardiography enables risk stratification, therapeutic guidance, and monitoring of disease progression or response to treatment. Future directions include artificial intelligence-assisted analysis, integration with remote monitoring, and multimodal imaging strategies to enhance diagnostic precision and individualized care. By aligning echocardiographic assessment with stage-specific HF pathophysiology, clinicians can improve outcomes through timely and tailored interventions.
Indexed as
Identifiers
41326844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.